| |
|
| |
News and Media Centre |
| |
|
|
| |
Press Releases |
| |
|
| |
March 2008
 Shasun Chemicals & Drugs Ltd
ICRA has assigned an A1+ rating to the Rs 878 Million sanctioned bank limits for Fund Based facilities and to the Rs 200 Million sanctioned bank limits for Non Fund Based facilities of Shasun Chemicals & Drugs Ltd (SCDL). This is the highest-creditquality rating assigned by ICRA to short-term debt instruments. |
| |
|
| |
Chennai, 25th February 2008
Shasun signs technology licensing agreement with Merck & Co., Inc.
Shasun today announced that it has entered into a non-exclusive licensing agreement with Merck
& Co., Inc. |
| |
|
| |
Chennai, January 28, 2008
Shasun Chemicals to set up new facilities in
Piscataway, US
Shasun Chemicals & Drugs Ltd; a leading
Indian CRAMS and API exporting pharmaceutical company, today
announced that it is setting up a process development facility in
Piscataway (New Jersey), United States. |
| |
|
| |
Mumbai, 16th October, 2007
Shasun Chemicals Q2 FY08 top line grows by 21 % at Rs.131.16 crore
Shasun Chemicals and Drugs Ltd., a leading pharma company focused on
manufacture of finished dosage, APIs (active pharmaceutical ingredients)
and the intermediates to global pharma, posted a 21% per cent growth in
revenue at Rs 131.16 crore for the Q2 FY07-08 as compared to Rs 108.38 crore
of Q2 FY06-07 on standalone basis. |
| |
|
| |
19th sept, 2007
Shasun Chemicals To Host Fifth International Conference On Catalysis &Amp; Process Chemistry Technologies
Shasun Chemicals & Drugs; a leading pharma
company focused on manufacture of Finished Dosage, APIs (Active Pharmaceutical
Ingredients) and intermediates to global pharma; today announced that world-renowned
process chemists and scientists will participate at the Fifth International Conference on
Process Chemistry and Technology. |
| |
10th July, 2007
Chennai Shasun Chemicals Signs Technology Licensing Agreement With Lundbeck
Shasun Chemicals and Drugs Ltd., a leading pharma company focused on manufacture of Finished Dosage, APIs (Active Pharmaceutical Ingredients) and intermediates to global pharma, posted a 110.49 per cent growth in consolidated revenue at Rs 793.34 crores for the financial year ended March 31, 2007 compared to Rs 376.90 crores in FY06. |
|
29th May, 2007
Chennai - Shasun Chemicals FY07 Consolidated Net Profit up 43.19 %
Shasun Chemicals & Drugs Ltd; today announced that it’s wholly-owned UK-subsidiary Shasun Pharma Solutions Ltd has entered into a non-exclusive licensing agreement with H Lundbeck A/S, a research based Danish company engaged in finding new drugs for treatment of CNS (Central Nervous System) disorders. |
| |
|
|
| |
|
|
